NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) News Today $12.14 +0.01 (+0.08%) (As of 05:19 PM ET) Add Compare Share Share Today's Range$12.11▼$12.6050-Day Range$12.10▼$15.0252-Week Range$11.09▼$22.11Volume788,476 shsAverage Volume1.87 million shsMarket Capitalization$1.29 billionP/E Ratio12.02Dividend YieldN/APrice Target$24.75 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to Post FY2024 Earnings of $1.33 Per Share, Zacks Research Forecastsamericanbankingnews.com - September 25 at 1:58 AMCatalyst Pharmaceuticals Inc. stock falls Thursday, still outperforms marketmarketwatch.com - September 21 at 7:43 PMLevel Four Advisory Services LLC Purchases New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - September 20 at 4:18 AMBTC Capital Management Inc. Takes $275,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - September 19 at 7:13 AMCatalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conferencefinance.yahoo.com - September 18 at 8:44 AMCatalyst Pharmaceuticals launches $500M mixed shelf offering - filingseekingalpha.com - September 9 at 8:40 PMWhy Is Catalyst (CPRX) Down 14% Since Last Earnings Report?finance.yahoo.com - September 8 at 3:40 PMSeptember Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)stocknews.com - September 8 at 2:11 PMUnraveling the Future of Catalyst Pharmaceuticals Inc (CPRX): A Deep Dive into Key Metricsfinance.yahoo.com - September 6 at 1:55 PM19,700 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Boulder Hill Capital Management LPmarketbeat.com - September 4 at 12:51 PMSwiss National Bank Trims Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - September 3 at 4:35 AMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Citigroup Inc.marketbeat.com - September 1 at 5:33 AMCatalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perilsseekingalpha.com - August 30 at 5:36 PM3 Pharma Stocks to Watch for Value in Septemberstocknews.com - August 29 at 3:21 PMPrincipal Financial Group Inc. Sells 18,527 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - August 29 at 4:49 AMZacks Research Brokers Cut Earnings Estimates for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - August 25 at 5:54 AMTower Research Capital LLC TRC Acquires 15,442 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - August 25 at 4:52 AM3 Value Pharma Stocks to Keep Watchingstocknews.com - August 24 at 6:05 PMCantor Fitzgerald Reiterates Catalyst Pharmaceuticals (CPRX) Overweight Recommendationmsn.com - August 23 at 2:07 AMCatalyst Pharmaceuticals (CPRX): Is Now the Time to Buy This Pharma Stock?stocknews.com - August 21 at 2:05 PMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Russell Investments Group Ltd.marketbeat.com - August 21 at 4:51 AMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Mirae Asset Global Investments Co. Ltd.marketbeat.com - August 18 at 4:24 AMCatalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancerfinance.yahoo.com - August 16 at 4:33 PMCatalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congressfinance.yahoo.com - August 14 at 6:25 PMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Barclays PLCmarketbeat.com - August 14 at 4:52 AMCantor Fitzgerald Maintains Catalyst Pharmaceuticals (CPRX) Overweight Recommendationmsn.com - August 12 at 1:48 AMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of "Moderate Buy" by Analystsmarketbeat.com - August 11 at 4:43 PM5 Analysts Have This to Say About Catalyst Pharmaceuticalsmarkets.businessinsider.com - August 11 at 3:47 PMCatalyst Pharmaceuticals (NASDAQ:CPRX) Rating Reiterated by HC Wainwrightmarketbeat.com - August 11 at 8:27 AMCatalyst Pharmaceuticals (NASDAQ:CPRX) Given New $27.00 Price Target at Cantor Fitzgeraldmarketbeat.com - August 11 at 8:14 AMH.C. Wainwright Keeps Their Buy Rating on Catalyst Pharma (CPRX)markets.businessinsider.com - August 11 at 6:59 AMCatalyst Pharmaceuticals Second Quarter 2023 Earnings: EPS: US$0.35 (vs US$0.21 in 2Q 2022)finance.yahoo.com - August 11 at 6:59 AMCatalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - August 10 at 8:41 AMCatalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 9 at 8:11 PMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Los Angeles Capital Management LLCmarketbeat.com - August 4 at 5:51 AMWhich is the Better Value Stock for August: Catalyst Pharmaceuticals, Inc. (CPRX) vs. Teva Pharmaceutical Industries (TEVA)?stocknews.com - August 3 at 2:44 PMArtemis Investment Management LLP Grows Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - August 3 at 11:50 AMTexas Permanent School Fund Corp Has $1.36 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - August 1 at 7:17 AMCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Down 9.1% in Julymarketbeat.com - July 31 at 4:52 AMGables Capital Management Inc. Sells 13,525 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - July 29 at 12:59 AMFY2023 EPS Estimates for Catalyst Pharmaceuticals, Inc. Raised by Cantor Fitzgerald (NASDAQ:CPRX)marketbeat.com - July 28 at 7:35 AMPharmaceutical CEO to retire from public company he co-foundedbizjournals.com - July 27 at 3:55 AMCatalyst Pharmaceuticals, Inc.: Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-Endfinanznachrichten.de - July 25 at 4:05 PMCatalyst Pharmaceuticals: Patrick McEnany to Retire as CEO by Year-End >CPRXmarketwatch.com - July 25 at 11:01 AMPatrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-Endfinance.yahoo.com - July 25 at 11:01 AMCatalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023finance.yahoo.com - July 24 at 8:11 AMQ2 2023 EPS Estimates for Catalyst Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:CPRX)marketbeat.com - July 24 at 1:33 AMRaymond James & Associates Has $923,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)marketbeat.com - July 23 at 4:12 AMWhere Catalyst Pharmaceuticals Stands With Analystsmarkets.businessinsider.com - July 21 at 2:50 PMSanthera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolonefinance.yahoo.com - July 19 at 7:20 AM Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Media Mentions By Week CPRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CPRX News Sentiment▼0.710.49▲Average Medical News Sentiment CPRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CPRX Articles This Week▼65▲CPRX Articles Average Week Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GPCR News AMRX News RYTM News AGIO News SMMT News ARVN News OPK News XNCR News AMLX News IRWD News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:CPRX) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.